Alzheimer’s disease patients with presenilin 1 (PSEN1) mutations commonly show parkinsonism in addition to dementia. Yet, whether these patients show dopaminergic deficit and response to L-dopa is largely unknown. We report a 43-year-old woman with a PSEN1 mutation (A434T) who showed right side dominant parkinsonism. As disease progressed, she developed bilateral parkinsonism which was markedly relieved by L-dopa. Amyloid (Florbetaben) positron-emission tomography (PET) showed cortical florbetaben uptake, relatively sparing the striatum. Initial dopamine transporter (FP-CIT) PET showed asymmetrically decreased FP-CIT uptake in the left striatum. We suggest that in Alzheimer’s disease patients with PSEN1 mutation, parkinsonism may be relieved by L-dopa when it is associated with presynaptic dopaminergic deficit.
SamsonWN, van DuijnCM, HopWC, HofmanA (1996) Clinical features and mortality in patients with early-onset Alzheimer’s disease. Eur Neurol36, 103–106.
2.
CacaceR, SleegersK, Van BroeckhovenC (2016) Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement12, 733–748.
3.
BatemanRJ, AisenPS, De StrooperB, FoxNC, LemereCA, RingmanJM, SallowayS, SperlingRA, WindischM, XiongC (2011) Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther3, 1.
4.
KimJ.H., Genetics of Alzheimer’s disease, Dement Neurocogn Disord17, 131–136.
5.
TakaoM, GhettiB, HayakawaI, IkedaE, FukuuchiY, MiravalleL, PiccardoP, MurrellJR, GlazierBS, KotoA (2002) A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: Presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol104, 155–170.
6.
CampionD, BriceA, HannequinD, TardieuS, DuboisB, CalendaA, BrunE, PenetC, TayotJ, MartinezM, et al. (1995) A large pedigree with early-onset Alzheimer’s disease: Clinical, neuropathologic, and genetic characterization. Neurology45, 80–85.
7.
FinckhU, Muller-ThomsenT, MannU, EggersC, MarksteinerJ, MeinsW, BinettiG, AlbericiA, HockC, NitschRM, GalA (2000) High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet66, 110–117.
8.
FrommeltP, SchnabelR, KuhneW, NeeLE, PolinskyRJ (1991) Familial Alzheimer disease: A large, multigeneration German kindred. Alzheimer Dis Assoc Disord5, 36–43.
9.
GustafsonL, BrunA, EnglundE, HagnellO, NilssonK, StensmyrM, OhlinAK, AbrahamsonM (1998) A 50-year perspective of a family with chromosome-14-linked Alzheimer’s disease. Hum Genet102, 253–257.
10.
LoperaF, ArdillaA, MartinezA, MadrigalL, Arango-VianaJC, LemereCA, Arango-LasprillaJC, HincapieL, Arcos-BurgosM, OssaJE, BehrensIM, NortonJ, LendonC, GoateAM, Ruiz-LinaresA, RosselliM, KosikKS (1997) Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA277, 793–799.
11.
MitchellSL (1999) Extrapyramidal features in Alzheimer’s disease. Age Ageing28, 401–409.
12.
BurnsJM, GalvinJE, RoeCM, MorrisJC, McKeelDW (2005) The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology64, 1397–1403.
KlunkWE, PriceJC, MathisCA, TsopelasND, LoprestiBJ, ZiolkoSK, BiW, HogeJA, CohenAD, IkonomovicMD, SaxtonJA, SnitzBE, PollenDA, MoonisM, LippaCF, SwearerJM, JohnsonKA, RentzDM, FischmanAJ, AizensteinHJ, DeKoskyST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci27, 6174–6184.
15.
AttemsJ, QuassM, JellingerKA (2007) Tau and alpha-synuclein brainstem pathology in Alzheimer disease: Relation with extrapyramidal signs. Acta Neuropathol113, 53–62.
16.
LiuY, SternY, ChunMR, JacobsDM, YauP, GoldmanJE (1997) Pathological correlates of extrapyramidal signs in Alzheimer’s disease. Ann Neurol41, 368–374.
17.
FahnS, MardsenCD, JennerP, TeychenneP (1986), Recent developments in Parkinson’s disease. Raven Press, New York.
18.
AhnHJ, ChinJ, ParkA, LeeBH, SuhMK, SeoSW, NaDL (2010) Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): A useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci25, 1071–1076.
19.
KangY, NaDL (2003) Seoul Neuropsychological Screening Battery (SNSB). Human Brain Research & Consulting, Incheon.
20.
RichardsS, AzizN, BaleS, BickD, DasS, Gastier-FosterJ, GrodyWW, HegdeM, LyonE, SpectorE, VoelkerdingK, RehmHL (2015) Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med17, 405–423.
21.
BarthelH, GertzHJ, DreselS, PetersO, BartensteinP, BuergerK, HiemeyerF, Wittemer-RumpSM, SeibylJ, ReiningerC, SabriO (2011) Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol10, 424–435.
SniderBJ, NortonJ, CoatsMA, ChakravertyS, HouCE, JervisR, LendonCL, GoateAM, McKeelDWJr, MorrisJC (2005) Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol62, 1821–1830.
24.
WinslowAR, MoussaudS, ZhuLY, PostKL, DicksonDW, BerezovskaO, McLeanPJ (2014) Convergence of pathology in dementia with Lewy bodies and Alzheimer’s disease: A role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain137, 1958–1970.
